Susan M. Domchek, MD
An analysis of the phase III OlympiAD study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) showed that treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA
Olaparib was well tolerated overall, according to Susan M. Domchek, MD, who presented the findings.
“It’s important that people recognize that nausea, fatigue, and anemia are the 3 major side effects. Nausea can be managed pretty readily by standard antiemetics and, when necessary, dose reduction. You need to let them know it might happen and encourage them to stay on and you get them through it.”
- Domchek SM, Robson M, Im S-A, Senkus E, et al. Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. Abstract P5-21-12.
- Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523-533.
... to read the full story